



## Appendix 19 - ESOPHAGEAL CANCER

### Approved settings/ treatment line

Approved settings/ treatment line	Protocols	Evidence level
<b>Perioperative chemotherapy</b>	5-Fluorouracil/ Leucovorin/ Docetaxel/ Oxaliplatin (FLOT)	Category 1, Preferred
	5-fluorouracil (Bolus & infusion)/ Oxaliplatin	Category 2A, Preferred
	5-fluorouracil (infusion)/ Oxaliplatin	Category 2A, Preferred
	Capecitabine/ Oxaliplatin	Category 2A, Preferred
	5-fluorouracil/ Cisplatin	Category 1
<b>Preoperative chemotherapy</b>	5-Fluorouracil + Cisplatin	Category 2B
<b>Preoperative chemoradiotherapy</b>	5-fluorouracil/ Cisplatin	Category 1
	5-fluorouracil/ Oxaliplatin	Category 1, Preferred
	Capecitabine/ Oxaliplatin	Category 1, Preferred
	Irinotecan/ Cisplatin	Category 2B
	Paclitaxel/ 5-fluorouracil	Category 2B
	Paclitaxel/ Capecitabine	Category 2B
	Paclitaxel/ Carboplatin	Category 1, Preferred
<b>Definitive Chemoradiation</b>	5-fluorouracil/ Oxaliplatin	Category 1, Preferred
	Capecitabine/ Oxaliplatin	Category 1, Preferred
	Paclitaxel/ Carboplatin	Category 1, Preferred
	5-fluorouracil/ Cisplatin	Category 1, Preferred
	Irinotecan/ Cisplatin	Category 2B
	Docetaxel/ Cisplatin	Category 2A
	Paclitaxel/ Cisplatin	Category 2A
	Paclitaxel/ 5-fluorouracil	Category 2B
	Paclitaxel/ Capecitabine	Category 2B
<b>Postoperative chemotherapy</b>	5-fluorouracil/ Oxaliplatin	Category 2A, Preferred
	Capecitabine/ Oxaliplatin	Category 2A, Preferred
<b>Postoperative chemoradiotherapy</b>	5-fluorouracil (Infusion) or Capecitabine	Category 2A
<b>1<sup>st</sup> line, locally advanced/ recurrent/ metastatic</b>	5-fluorouracil/ Cisplatin	Category 2A, Preferred
	5-fluorouracil/ Oxaliplatin	Category 2A, Preferred
	Capecitabine/ Oxaliplatin	Category 2A, Preferred
	Capecitabine/ Cisplatin	Category 2A, Preferred
	5-fluorouracil/ Irinotecan	Category 2A
	Paclitaxel/ Cisplatin	Category 2A
	Paclitaxel/ Carboplatin	Category 2A
	5-Fluorouracil	Category 2A
	Capecitabine	Category 2A
	Docetaxel	Category 2A
	Paclitaxel	Category 2A
	Docetaxel/ cisplatin/ 5-fluorouracil	Category 2A
	Docetaxel/ oxaliplatin/ 5-fluorouracil	Category 2A
	Docetaxel/ carboplatin/ 5-fluorouracil	Category 2B
	Epirubicin/ Cisplatin/ 5-fluorouracil	Category 2B
	Epirubicin/ Cisplatin/ Capeitabine	Category 2B
	Epirubicin/ Oxaliplatin/ 5-fluorouracil	Category 2B
	Epirubicin/ Oxaliplatin/ capecitabine	Category 2B



Approved settings/ treatment line	Protocols	Evidence level
<b>2<sup>nd</sup> line, locally advanced/ recurrent/ metastatic</b>	Ramucirumab/ Paclitaxel	Category 1 EGJ Adeno carcinoma, Category 2A Adenocarcinoma
	Docetaxel	Category 1, Preferred
	Paclitaxel	Category 1, Preferred
	Irinotecan	Category 1, Preferred
	Trifluridine/ Tipiracil	Category 1, Preferred EGJ
	5-Fluorouracil/ Irinotecan	Category 2A, Preferred
	Pembrolizumab	Category 2A, Preferred
	Ramucirumab	Category 1 Adenocarcinoma, Category 2A EGJ
	Irinotecan/ Cisplatin	Category 2A
	Docetaxel/ Irinotecan	Category 2B
	5-fluorouracil/ irinotecan/ ramucirumab	Category 2B, Adenocarcinoma